Tian Zhang, MD, MHS, UT Southwestern Medical Center

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Tian Zhang, MD, discusses the investigation of the combination of enfortumab vedotin plus pembrolizumab in the phase 3 EV-302 trial in the frontline setting for metastatic urothelial cancer.

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE trial, evaluating the combination ipilimumab plus nivolumab, followed by nivolumab with or without cabozantinib, in patients with advanced renal cell cancer.

Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.

Tian Zhang, MD, discusses emerging biomarkers that are helping to guide treatment for patients with renal cell carcinoma.

Tian Zhang, MD, discusses the goal of the ongoing PDIGREE trial examining nivolumab and ipilimumab plus cabozantinib in patients with metastatic untreated renal cell cancer.

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Tian Zhang, MD, discusses data from the randomized phase III IMvigor130 trial, which compared the safety and efficacy of atezolizumab in combination with platinum-based chemotherapy, atezolizumab monotherapy, and chemotherapy alone, in the frontline treatment of patients with metastatic urothelial cancer.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses some of the challenges associated with administering vaccines to patients with renal cell carcinoma.